US Federal Circuit Will Not Stand In Way Of Gilenya Generics
Novartis: ‘Over Twenty ANDA Products Could Enter The US Market’
ANDA sponsors targeting Novartis’s Gilenya have been informed by the US Court of Appeals for the Federal Circuit that at an ‘at-risk’ launch is possible, after the originator’s latest petition to the court was denied as it seeks a ruling from the US Supreme Court.
